Clinicians and Mental Health Care; Schizophrenia Tx Flops; Cobenfy for Alzheimer’s?

Healthcare workers cited concerns about confidentiality as a barrier to getting treatment for mental health issues, according to a national internet panel survey. (Morbidity and Mortality Weekly Report)

Iclepertin, an investigational glycine transporter 1 inhibitor, missed both primary and key secondary endpoints for improving cognitive impairment in adults with schizophrenia in the 6-month phase III CONNEX trial, said developer Boehringer Ingelheim.

Women who were receiving treatment for opioid use disorder (OUD) were less likely to be prescribed birth control compared with those who were not, an analysis of claims data showed. (JAMA Internal Medicine)

Researchers identified 298 regions of the genome that increase the risk for bipolar disorder. (Nature)

National data confirm disparities in access to telepsychiatry for children. (American Journal of Psychiatry)

Girls who had their first period before the age of 11.5 years had 47% higher odds for developing disordered eating, according to national survey data. (Pediatric Research)

Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer’s disease psychosis, agitation, and cognition? Bristol Myers Squibb executives seem to think so. (CNBC)

Lykos Therapeutics, developer of the once-rejected drug midomafetamine (MDMA) capsules for post-traumatic stress disorder, said it had another productive meeting with the FDA last week and continues to “chart a path forward for an independent third-party review” of phase III trial data.

No surprise here: chronic stress was linked with depressive symptoms 10 years later, a population-based cohort study of German students found. (Scientific Reports)

Here’s how one jail in rural Maine manages inmates with OUD. (New York Times)

A meta-analysis found that interventions aimed at reducing mental health stigma among young people may help in the short-term. (JAMA Network Open)

Please enable JavaScript to view the comments powered by Disqus.